Hepatic impairment patients: dosage adjustment is not required.
Renal impairment patients
Doses of tenofovir disoproxil fumarate should be modified by adjustment of the dosing interval in patients with renal impairment according to their creatinine clearance (Clcr):
Tefostad T300 is administered orally once daily without regard to meals.
Known hypersensitivity to tenofovir disoproxil fumarate or any ingredient in the formulation
Mild gastrointestinal effects, particularly diarrhoea, nausea and vomiting, abdominal pain, flatulence, dyspepsia, and anorexia. Serum-amylase concentrations may be raised and pancreatitis has been reported. Hypophosphataemia. Skin rashes. Peripheral neuropathy, headache, dizziness, insomnia, depression, asthenia, sweating, and myalgia. Raised liver enzymes, hypertriglyceridaemia, hyperglycaemia, and neutropenia. Renal impairment, (including Fanconi syndrome). Lactic acidosis, severe hepatomegaly and steatosis.